Upstream & Downstream Processing

Podcast: On board the Cell Shuttle with Cellares

Cellares Corporation’s CEO Fabian Gerlinghaus talks about the current limitations in cell therapy production and how, with $82 million in hand, its Cell Shuttle technology could resolve these. Tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle. Having raised $82 million in its latest funding round, co-founder and CEO Fabian Gerlinghaus spoke about how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space on…

Eppendorf $100m of capacity expansions reflects record year

Eppendorf says it will continue investing in production capabilities and infrastructure as it reports a record 12 months. German life sciences tool provider Eppendorf reported revenues of €967 million($1.16 billion) for its fiscal year 2020, up 20.3% on the year prior. “2020 was by far the most successful fiscal year for the Eppendorf Group,” co-CEOs Eva van Pelt and Peter Fruhstorfer said in a joint statement. Like many of its fellow bioprocess suppliers, growth in sales across many of Eppendorf’s…

SBI hoping to kickstart digital bioprocessing revolution through aquila buy

Scientific Bioprocessing (SBI) says it is aiming to create a digital platform to enhance biopharmaceutical workflow through the acquisition of smart sensor and data analytics firm aquila biolabs. Life sciences tool supplier Scientific Industries, through its subsidiary SBI, has acquired aquila biolabs, adding smart sensors and data analytics software for bioprocessing along with facilities in Baesweiler, Germany. “From the earliest interactions with the aquila biolabs team, it became really apparent that we shared the vision of developing technologies that can…

Avantor upping single-use capacity by 30% in response to huge demand

Avantor says investments in facilities in North Carolina, Massachusetts, and The Netherlands will help feed the surge in demand for single-use equipment driven by a robust biologics sector and the COVID-19 pandemic. Sean DeFusco, general manager of single-use solutions/fluid handling at Avantor, told BioProcess Insider the firm will increase its single-use manufacturing footprint by 30% in the United States and Europe along with doubling cleanroom space. “So far, we expanded our Morrisville, North Carolina single-use facility and we’re nearing completion…

Single-use lead times up to 12 months as COVID takes its toll

Some biomanufacturers are waiting up to a year for single-use equipment, according to ABEC. And while vendors are expanding capacity these projects will take months to come online. Early in the COVID-19 pandemic, single-use bioprocess systems and materials were highlighted as necessary tools in the development and commercial manufacture of potential vaccines and therapies. The speed and flexibility needed to make novel vaccines, including mRNA, DNA, and viral vectors, meant those platforms were largely built on single-use technologies. Coupled with…

Vendors continuing to reap the COVID windfall

Danaher expects COVID-19 vaccine and therapy-related revenue for its bioprocess businesses Pall and Cytiva to reach $2 billion, while the pandemic fuelled “an exceptionally strong start” to Sartorius’s 2021. In June last year, the evolving coronavirus pandemic was marked out as a $14 billion opportunity for bioprocess vendors by analysts. Ten months on, with several vaccines and therapies being used commercially and several more moving through the clinic, the service firms are experiencing unprecedented demand for their equipment and tools…

Oxford Biomedica working to optimize vector production platform

Oxford Biomedica is optimizing its vector production system to boost yields and accelerate production in response to growing demand. The UK gene and gene therapy firm and contract development and manufacturing organization (CDMO) talked about efforts to improve its vector production platform last week during its Q4 presentation. The main aim – according to chief scientific officer Kyri Mitrophanous – is to increase viral vector production capacity and remain competitive. “We continue to invest in the lentiviral vector platform in…

Preparation key to gene therapy commercialization, MilliporeSigma

Gene therapy firms are under pressure to get to market quickly according to an expert from MilliporeSigma, who says process development and tech transfer are significant hurdles. The ability to treat – or cure – disease at the genetic level in a targeted manner is an attractive proposition for drug companies. The challenge now is to make these therapies in a cost and time efficient manner according to Ratish Krishnan, associate director for cell and gene therapy bioprocessing at Milliporesigma.…

BPI West: Modular tech key to rapid COVID-19 vaccine development

The coronavirus pandemic has underlined the benefits of modular manufacturing according to an expert who says the approach has been key to accelerating vaccine production. SARS-CoV-2, the virus that causes COVID-19, was first isolated in December 2019 and sequenced a month later. The first vaccines against it were developed, tested, and approved about a year after the first was identified. The record speed with which industry created the COVID-19 shots is testament to vaccine industry efforts, according to John Yoshi…

CGT firms making progress but manufacturing remains a hurdle, says analyst

Cell and gene therapy developers have yet to address delivery, production and safety challenges but progress is being made. The conclusion came from RBC Capital Markets, which published analysis of trends in the cell and gene therapy sectors this week. According to executives quizzed by the market research firm, the biggest challenges that modern gene therapy firms face are pretty similar to those encountered by pioneers in the field a couple of decades ago. “Gene therapies hold considerable promise in…